Zafgen, Inc. (NASDAQ:ZFGN)
Industry: Healthcare

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Current Quote*
Last: $9.900
Change: -1.120
Book: $5.334
Volume: 98,798

As Of: 11/14 14:48 ET
*Quotes delayed by 20min.

Graphs for ZFGN


3 Month Graph


6 Month Graph


1 Year Graph